Vanda Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vanda Pharmaceuticals Inc. on November 12, 2010. The filing discloses the appointment of a new Senior Vice President, Chief Financial Officer, Treasurer, and Secretary.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change is the appointment of James Patrick Kelly to the role of Senior Vice President, Chief Financial Officer, Treasurer, and Secretary, effective December 13, 2010.
Management Commentary and Compensation Details
- Base Salary: $285,000 annually.
- Target Bonus: 40% of annual base salary.
- Stock Options: Grant of 150,000 nonstatutory stock options at fair market value. Vesting schedule: 25% after 12 months, with the remainder vesting in equal monthly installments over the subsequent 36 months.
- Restricted Stock Units (RSUs): Grant of 50,000 RSUs. Vesting schedule: 25% on January 1, 2012, and 25% annually on January 1 for the next three years.
- Change of Control: Full acceleration of unvested options and RSUs if the Company undergoes a change of control and Mr. Kelly is terminated without cause or resigns for good reason within 24 months.
- Severance: Upon termination without cause or for good reason, Mr. Kelly is eligible for 12 months of base salary, a lump-sum target bonus, COBRA premium coverage, and an additional three months of option vesting with a six-month exercise window.
Investor Verification Points
- Verify the effective start date of December 13, 2010, for the new CFO.
- Confirm the total equity grant size (150,000 options and 50,000 RSUs) relative to the company's outstanding share count.
- Review the specific definitions of "good reason" and "change of control" in the employment agreement to assess potential dilution or cash outflow risks.
- Note that the filing contains no financial performance data for the period.